{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Granulomatous+Disease%2C+Chronic%2C+X-linked&page=2",
    "query": {
      "condition": "Granulomatous Disease, Chronic, X-linked",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Granulomatous+Disease%2C+Chronic%2C+X-linked&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T09:51:31.834Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03513328",
      "title": "Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Failure Syndrome",
        "Thalassemia",
        "Sickle Cell Disease",
        "Diamond Blackfan Anemia",
        "Acquired Neutropenia in Newborn",
        "Acquired Anemia Hemolytic",
        "Acquired Thrombocytopenia",
        "Hemophagocytic Lymphohistiocytoses",
        "Wiskott-Aldrich Syndrome",
        "Chronic Granulomatous Disease",
        "Common Variable Immunodeficiency",
        "X-linked Lymphoproliferative Disease",
        "Severe Combined Immunodeficiency",
        "Hurler Syndrome",
        "Mannosidosis",
        "Adrenoleukodystrophy"
      ],
      "interventions": [
        {
          "name": "Thiotepa--single daily dose",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa--escalated dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Months",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "3 Months to 39 Years"
      },
      "enrollment_count": 6,
      "start_date": "2018-06-15",
      "completion_date": "2023-02-19",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03513328"
    },
    {
      "nct_id": "NCT06559176",
      "title": "A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD )",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease",
        "Granulomatous Disease, Chronic"
      ],
      "interventions": [
        {
          "name": "PM359",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Prime Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2024-10-17",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Bethesda, Maryland • Nashville, Tennessee",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06559176"
    },
    {
      "nct_id": "NCT07113743",
      "title": "Part B- G1X-CGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease (CGD)"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Eltrombopag",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "pCCLChimGp91lentiviral vector containing the human gp91 phox (CYBB) gene",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "3 Years to 60 Years"
      },
      "enrollment_count": 10,
      "start_date": "2025-09-10",
      "completion_date": "2029-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07113743"
    },
    {
      "nct_id": "NCT00001405",
      "title": "Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Granuloma",
        "Granulomatous Disease, Chronic",
        "Leukocyte Disease",
        "Genetic Disease, X-Linked",
        "Genetic Disease, Inborn"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 850,
      "start_date": "1994-02-27",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001405"
    },
    {
      "nct_id": "NCT05463133",
      "title": "Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Pheripheral blood stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emapalumab-Izsg",
          "type": "DRUG"
        },
        {
          "name": "Tociluzumab",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "4 Years to 65 Years"
      },
      "enrollment_count": 50,
      "start_date": "2022-07-08",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05463133"
    },
    {
      "nct_id": "NCT01821781",
      "title": "Immune Disorder HSCT Protocol",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immune Deficiency Disorders",
        "Severe Combined Immunodeficiency",
        "Chronic Granulomatous Disease",
        "X-linked Agammaglobulinemia",
        "Wiskott-Aldrich Syndrome",
        "Hyper-IgM",
        "DiGeorge Syndrome",
        "Chediak-Higashi Syndrome",
        "Common Variable Immune Deficiency",
        "Immune Dysregulatory Disorders",
        "Hemophagocytic Lymphohistiocytosis",
        "IPEX",
        "Autoimmune Lymphoproliferative Syndrome",
        "X-linked Lymphoproliferative Syndrome"
      ],
      "interventions": [
        {
          "name": "Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 20,
      "start_date": "2013-04-29",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821781"
    },
    {
      "nct_id": "NCT01063309",
      "title": "Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Atherosclerosis",
        "Chronic Granulomatous Disease (CGD)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 156,
      "start_date": "2010-01-05",
      "completion_date": "2020-08-26",
      "has_results": false,
      "last_update_posted_date": "2021-07-28",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01063309"
    },
    {
      "nct_id": "NCT01851460",
      "title": "Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Granulomatous Diseases (CGD) and Liver Lesions"
      ],
      "interventions": [
        {
          "name": "Cool-tip RF Ablation System",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-05-08",
      "completion_date": "2020-03-24",
      "has_results": false,
      "last_update_posted_date": "2020-03-26",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01851460"
    },
    {
      "nct_id": "NCT00730314",
      "title": "Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Anemia",
        "Granuloma",
        "Wiskott-Aldrich Syndrome",
        "Chediak Higashi Syndrome",
        "Osteopetrosis",
        "Neutropenia",
        "Thrombocytopenia",
        "Hurler Disease",
        "Niemann-Pick Disease",
        "Fucosidosis"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 25,
      "start_date": "2008-08",
      "completion_date": "2015-08",
      "has_results": false,
      "last_update_posted_date": "2016-06-23",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00730314"
    },
    {
      "nct_id": "NCT03910452",
      "title": "Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Chronic Granulomatous Disease"
      ],
      "interventions": [
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Allogeneic peripheral blood stem cell",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "4 Years to 65 Years"
      },
      "enrollment_count": 4,
      "start_date": "2019-10-28",
      "completion_date": "2034-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-24T09:51:31.834Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03910452"
    }
  ]
}